Search

Terms & Conditions

EHA offers visitors a wide variety of information and a range of online services via its website.

Read more

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Read more

Target audience

You are a hematologist working at an academic center or a large community hospital that is known for running clinical trials.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

Read more

Adult Acute Lymphoblastic Leukemia

The Specialized Working Group on Adult Acute Lymphoblastic Leukemia consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL. This includes the leaders of the national ALL study groups in Europe.

Read more